JP3465298B2 - Transpiration device - Google Patents

Description

Detailed Description of the Invention

[0001]

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a vaporizing device for vaporizing chemicals such as fragrances, deodorants, germicides and insecticides.

[0002]

2. Description of the Related Art As conventional evaporation devices, those shown in FIGS. 49 and 50 are known. That is, the evaporation device is composed of a device body 61 and a chemical liquid cartridge 62 that is detachably mounted in the device body 61. The apparatus main body 61 has an outer case 63, an evaporation port 64 is opened on the upper surface of the outer case 63, and an insertion port 65 is formed on the lower surface. A tubular portion 66 is provided above the inside of the outer case 63, and a female screw portion 67 is formed on the inner periphery of the lower portion of the tubular portion 66. Further, a heater 69 having an insertion hole 68 at the center is arranged at the upper end of the tubular portion 66, and a cord wired from a power cord port 70 is connected to the heater 69.

On the other hand, the chemical liquid cartridge 62 has a chemical liquid container 72 having a circular cross section in which a chemical liquid 71 having a predetermined effect such as fragrance is contained, and the female screw portion 67 is provided on the upper peripheral portion of the chemical liquid container 72. A male screw portion 73 that is screwed into is formed. Further, a cap 74 is fitted to the upper end opening of the chemical liquid container 72, the upper end of which projects outside the chemical liquid container 72 and the lower end of which is the bottom surface of the chemical liquid container 72 at the center of the cap 74. Liquid absorbing core 75 extended to the vicinity
Is fitted.

In such a structure, in use, the apparatus main body 61 is lifted up, and the chemical liquid cartridge 62 is inserted into the external case 63 through the insertion port 65 and rotated.
Thereby, as shown in FIG. 50, the male screw portion 73 provided on the upper end portion of the chemical liquid container 72 is screwed into the female screw portion 67 provided on the tubular portion 66, and the chemical liquid cartridge 62 is attached to the apparatus main body 61. Be loaded into. Thus, when the chemical liquid cartridge 62 is loaded, the upper end of the liquid absorbent core 75 is loosely inserted into the insertion hole 68 of the heater 69. In this state, the heater 69 operates to generate heat, so that the liquid absorbent core 7
The drug component evaporates from 5 and diffuses to the outside through the evaporation port 64.

[0005]

However, in such a conventional evaporation device, the liquid absorption core 75 is arranged vertically and the upper end portion thereof is projected to the outside of the chemical liquid container 72. Therefore, as the remaining amount of the chemical liquid 71 decreases and the liquid level of the chemical liquid 71 decreases, the portion of the liquid absorbent core 75 immersed in the chemical liquid 71 decreases. When the portion immersed in the medicine 71 decreases, the liquid absorption amount of the liquid absorbent core 71 decreases accordingly, and the amount of the chemical liquid 71 leached to the upper end also decreases. As a result, the amount of transpiration from the upper end of the liquid absorbent core 71 also gradually decreases as the residual amount of the liquid medicine 71 decreases, and thereby the fragrance effect of the fragrance and the deodorant effect of the deodorant are also exerted. It gradually decreases, and it is not possible to perform variable transpiration such that the transpiration amount is appropriately increased or decreased during the use period.

Further, since the heater 69 has a structure in which the heater 69 is constantly operated to generate heat to evaporate, a large current is required per unit time. Therefore, when the battery is used as a power source, the usable period is extremely short. Becomes Therefore, there is no choice but to adopt a method of connecting the cord to an AC power source for home use, and it is difficult to realize a portable evaporation device that can be carried to any place by using a battery as a power source.

The present invention has been made in view of such conventional problems, and it is possible to effectively evaporate a drug without being influenced by the progress of a use period and with a small power consumption. It is an object of the present invention to provide an evaporation device.

[0008]

In order to solve the above-mentioned problems, in the present invention, a drug part in which a drug capable of evaporating is held and a plurality of heating devices for heating corresponding parts of the drug part, respectively. A heating means having a surface and a control means for controlling a heating state of the plurality of heating surfaces , wherein the heating means is a flat surface.
A plane substrate and a plurality of electrodes stacked on this plane substrate
A conductive layer and a resistor laminated on this conductive layer.
It Alternatively, the heating means comprises a single common electrode and a plurality of
An individual electrode, and the control means is not the common electrode.
The corresponding heating is performed by forming an energized state with one of the individual electrodes.
Heat the surface.

[0009]

In the above structure, the plurality of heating surfaces provided on the heating means are controlled by the control means to form a heating state. As a result, the corresponding part of the drug part is heated by the heating surface forming the heated state, and only the drug held in the part evaporates.

[0010]

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS An embodiment of the present invention will be described below with reference to the drawings. That is, FIGS. 1 to 7 show the first embodiment of the present invention, and as shown in FIG.
It has a lower case 3 and an upper case 4, one side of which is pivotally attached via a hinge 2. The lower case 3 is a box body having an opening on the upper surface, and the battery cover 6 is provided in the opening 5 provided on the bottom surface.
Is detachably fitted. A lower partition plate 7 is mounted on the inner peripheral portion of the upper end of the lower case 3, and a first printed circuit board 8 is mounted on the lower surface of the lower partition plate 7. A battery 9 is detachably attached to the lower surface of the first printed circuit board 8, and the upper case 4 is attached to the upper surface thereof.
One end of the electrical system connect cable 10 extending to the side is connected.

The upper case 4 is formed of a resin having chemical resistance, and has a card insertion port 11 at the lower end of the side and a transpiration port 12 at the end of the upper surface. In addition, the upper partition plate 13 is arranged inside,
As a result, an evaporation space 14 is defined by the upper partition plate 13 and the lower partition plate 7 in both cases 3 and 4, and the evaporation space 14 communicates with the evaporation port 12.

A card insertion slot 1 is provided on the lower partition plate 7.
The evaporative drug solution card 15 inserted through 1 is placed. As shown in FIG. 2, the evaporated chemical liquid card 15 is
It is composed of a circular base 16 and a square-shaped chemical solution holding portion 17 provided at the center of the upper surface of the base 16. The base 16 is formed of a heat-resistant material such as heat-resistant resin or metal, and the chemical solution holding portion 17 includes an aromatic agent, a deodorant,
It is composed of microcapsules in which a liquid medicine such as a bactericide, an insecticide and the like is evaporated to exhibit a predetermined effect, and a binder carrying the microcapsules.

On the other hand, on the upper surface side of the upper partition plate 13,
A second printed circuit board 18 is arranged, and a thermal head 19 that is in close contact with the chemical solution holding unit 17 is provided at the center of the lower surface of the second printed circuit board 18. As shown in FIG. 3, the thermal head 19 includes 16 thermal dots A-1 to A-1 divided into a matrix of 4 rows and 4 columns.
It has D-4.

A third printed circuit board 20 is arranged on the second printed circuit board 18, and the two printed circuit boards 18 and 20 are electrically connected to each other. A control LSI 21 is provided on one end side of the third printed circuit board 20, and the electric system connect cable 1 is provided on the other end side.
0 is connected. As shown in FIG. 4, the control LSI 21 includes a CPU 22, a program ROM 23, a thermal head driver 24, etc., and receives a control power supply and a clock of a predetermined frequency. Also, CPU2
A signal from a normally open evaporation ON SW 25 is input to 2, and an evaporation power source is connected to the thermal head driver 24.

On the other hand, as shown in FIG. 5, 16 thermal dots A-1 to D provided on the thermal head 19 are provided.
-4 is composed of heating elements 26 ... Connected in parallel. Heating element 26 forming each dot A-1 to D-4
Has 16 control switches a, one end of which is grounded and the other end of which is provided in the thermal head driver 24.
It is connected to one of the fixed contacts -1 to d-4. The other fixed contacts of the control switches a-1 to d-4 are
It is connected to the evaporation power source and the movable contact is O from the CPU 22.
It is configured to be driven by an N-OFF signal. Both the evaporation power source and the control power source are supplied from the battery 9.

Next, the operation of this embodiment having the above configuration will be described with reference to the flowcharts of FIGS. That is, the CPU 22 starts its operation when the control power source is turned on, and determines whether or not the evaporation ON SW 25 has been pressed (SA1). If the evaporation ON SW 25 is pressed, 16 thermal dots A in 4 rows and 4 columns
-1 to D-4 are sequentially executed (SA2 to SA1
7).

The control of each of the thermal dots A-1 to D-4 has the same contents, and as shown in FIG. 7, an ON signal of the corresponding thermal dot is issued (SB1). Thereafter, the 5 ms timer is activated, and the corresponding thermal dot A-1 to D-4 continues to be in the on state (SB2) during that time, and the thermal dot maintained in the on state at the time when 5 ms elapses. Turn off (SB3).

Therefore, by the processing of SB1 to SB3, the control switches a-1 to d-4 corresponding to the thermal dots A-1 to D-4 shown in FIG. The heating resistor 26 of D-4 operates for heating. As a result, in the drug solution holding unit 17, only the portion where the heat-generating resistor 26 that has generated heat is in close contact is heated, the microcapsule is destroyed, and the drug enclosed in the microcapsule evaporates.

Further, the processing of SB1 to SB3 is sequentially executed on the 16 thermal dots A-1 to D-4, whereby the thermal dots A-1 to D-4 in the chemical solution holding section 17. 16 areas corresponding to 5m each
Each s is heated in time division. At this time, generally when using a battery as a power source, the total energy that can be extracted from the battery decreases in inverse proportion to the current per unit, and
The maximum current is also limited. But, as mentioned above,
By heating the 16 thermal dots A-1 to D-4 in increments of 5 ms, which is a minute time, the current per unit can be kept low, and even if the battery 9 is used as a vaporization power source and is portable, Evaporation can be performed without any trouble.

8 to 11 show the second embodiment of the present invention, and as shown in FIG.
7 is composed of a square base 16 and a chemical solution holding portion 17 provided on the base 16. Further, as shown in FIG. 9, the three-division thermal head 28 has three thermal heads. It has heads A, B, and C. On the other hand, FIG.
As shown in 0, the CPU 22 has a large transpiration amount ON.
Signals from the SW 29, the transpiration amount transpiration ON SW 30, and the transpiration amount small transpiration ON SW 31 are input. further,
As shown in FIG. 11, the thermal head driver 24 is provided with control switches 24a, 24b, 24c connected to the thermal heads A, B, C, respectively. Each control switch 24a, 24b, 24c is a normally open type
It is configured to be driven by a signal from the PU 22.

In this embodiment having the above structure, C
The PU 22 operates according to the flowchart shown in FIG. 12, and first determines whether or not the large transpiration amount ON SW 29 has been pressed (SC1). Maximum transpiration amount ON SW29
When is pressed, the ON signal (S
C4), the ON signal of the thermal head B (SC5), and the ON signal of the thermal head C are issued (SC6). next,
After the thermal heads A, B, C are kept on for 5 ms by the 5 ms timer (SC7), the thermal heads A, B, C are turned off (SC8). Therefore, when the large transpiration amount ON SW 29 is pressed, the three thermal heads A, B, C all operate to heat, whereby the entire surface of the chemical solution holding unit 17 is heated and the chemical solution holding unit 17 is heated. The maximum amount of transpiration of the drug is from.

When the large transpiration amount ON SW29 is not pressed and the medium transpiration amount ON SW30 is pressed, the process proceeds from SC2 to SC5 to output the ON signal of the thermal head B, and then to the thermal head B. The ON signal of the head C is output (SC6). Then, after the thermal heads B and C are kept on for 5 ms by the 5 ms timer (SC7), the OFF signals of the thermal heads B and C are output (SC8). Therefore, the amount of transpiration is ON SW30
When pressing the button, two thermal heads B and C
The heating operation of the
The area of ⅓ is heated, and the amount of the transpiration of the drug from the drug solution holding unit 17 becomes an intermediate level of about ⅔ of the maximum value.

If the large transpiration amount ON SW29 and the medium transpiration amount ON SW30 are not pressed and the small transpiration amount ON SW31 is pressed, the process proceeds from SC3 to SC6, and the thermal head C Issue an ON signal.
Then, after the thermal head C is kept on for 5 ms by the 5 ms timer (SC7), an OFF signal of the thermal head C is output (SC8). Therefore, when the small transpiration amount ON SW 31 is pressed, one thermal head C is heated to heat a 1/3 region in the chemical solution holding unit 17,
The amount of transpiration of the drug from the drug solution holding unit 17 is also about 1/3 of the maximum value. Therefore, this second
In the embodiment, the transpiration amount is large, medium, and small ON SW29,
By selectively operating 30, 31, the transpiration amount can be 3
By setting the stages, it is possible to vaporize an appropriate amount of the drug according to the volume of the space in which the vaporization device is used.

FIGS. 13 to 18 show a third embodiment of the present invention. As shown in FIGS. 13 and 14, the evaporated chemical solution card 32 is provided on the circular base 16 and on the base 16. And a square drug solution holding portion 33. The chemical solution holding portion 33 has a four-row configuration, and each row is coated with a first transpiration chemical solution 33A, a second transpiration chemical solution 33B, a third transpiration chemical solution 33C, and a fourth transpiration chemical solution 33D.
The first to fourth transpiration chemicals 33A to 33D are, for example, fragrances having different fragrances, or fragrances, deodorants,
A microcapsule is encapsulated with a drug having different characteristics, such as a bactericidal agent or an insecticide, and the microcapsules are supported by a binder.

Further, as shown in FIG. 15, the four-divisional thermal head 34 has the thermal heads A, B, C and D of the four evaporative chemicals. On the other hand, as shown in FIG. 16, the CPU 22 has the first chemical liquid evaporation ON SW35.
A, 2nd chemical evaporation ON SW35B, 3rd chemical evaporation ON
Signals from the SW 35C and the fourth chemical liquid evaporation ON SW 35D are input. Further, as shown in FIG. 17, each of the thermal heads A,
Control switches 24a to 24d connected to B, C, and D are provided. Each of the control switches 24a to 24d is a normally open type and is configured to be driven by a signal from the CPU 22.

In the present embodiment having the above configuration, C
The PU 22 operates according to the flowchart shown in FIG. 18, and first determines whether or not the first chemical liquid evaporation ON SW 35A has been pressed (SD1). First chemical vaporization ON SW35
When A is pressed, the ON signal of the thermal head A is output (SD5), the ON state of the thermal head A is continued for 5 ms by the 5 ms timer (SD9), and then the OFF signal of the thermal head A is output. (SD10).

Therefore, the first chemical liquid evaporation ON SW35
When pressing A, four thermal heads A,
Of the B, C, and D, only the thermal head A operates for heating, and only the first evaporated chemical liquid 35A is heated in the chemical liquid holding portion 33. As a result, only the microcapsules of the first evaporated chemical liquid 33A are destroyed, and the first evaporated chemical liquid 35A is destroyed.
Only the drug with the property of is transpired.

If the second chemical vaporization ON SW 35B is pressed without pressing the first chemical vaporization ON SW 35A, the process proceeds from SD2 to SD6, the ON signal of the thermal head B is issued, and the 5 ms timer is used. After the ON state of each thermal head B is continued for 5 ms (SD
9), turn off the thermal head B signal (SD1
0). Therefore, when the second chemical liquid vaporization ON SW 35B is pressed, only the thermal head B is heated so that only the chemicals of the second vaporized chemical liquid 33B are vaporized.

Similarly, the third chemical liquid evaporation ON SW
When 35C is pressed, the ON signal of the thermal head C is output (SD7), the ON signal of the fourth chemical liquid evaporation ON SW 35D is output (SD8), and the ON state is continued for 5 ms by the 5 ms timer (SD9). ), And an OFF signal is output (SD10). Therefore, in the third embodiment, it is possible to vaporize the chemical liquids having different characteristics by arbitrarily turning on any of the four chemical liquid vaporization ON SWs 35A to 35D. Therefore, one evaporation device can be used for multiple purposes depending on the required drug effect.

19 to 24 show the fourth embodiment of the present invention. As shown in FIGS. 19 and 20, the evaporated chemical solution card 36 is provided on the rectangular base 16 and on the base 16. Similarly, it is composed of a rectangular drug solution holding portion 17. Further, as shown in FIG. 21, the four-division thermal head 34 includes four thermal heads A, B, C,
The four thermal heads A to D are arranged in a rectangular shape corresponding to the shape of the chemical solution holding portion 17. The overall configuration of the fourth embodiment is the same as that of FIG. 4 except that the RAM 37 is provided as shown in FIG.
The thermal head driver 24 and the four-division thermal head 34 have the same circuit configuration as that of the first embodiment shown in FIG. 17 and the third embodiment shown in FIG.

As shown in FIG. 23, the RAM 37 is provided with an evaporation management memory KR. The transpiration management memory KR has 4 bits and has registers AKR, BKR, CKR, DKR each of which is composed of 1 bit.

In the present embodiment having the above configuration, C
The PU 22 operates according to the flowchart shown in FIG. 24, and first resets each bit of the evaporation management memory KR to 0 (SE1). Next, until the evaporation ON SW 25 is pressed (SE2), if the evaporation ON SW 25 is pressed, it is determined whether the AKR is in the reset state (SE3). If the AKR is in the reset state and the evaporation ON SW 25 is operated for the first time, AK
After setting R (SE7), turn on thermal head A
Send a signal (SE8). Subsequently, after the thermal head A is kept on for 5 ms by the 5 ms timer (SE15), an OFF signal of the thermal head A is issued (SE16), and the process returns to SE2.

Also, the user turns on the second evaporation ON SW2.
When the operation of 5 is performed, the process proceeds from SE2 to SE3, but at this time, "1" is already set in AKR. Therefore, the process proceeds from SE3 to SE4, and it is determined whether or not the BKR is in the reset state. At this point, BKR
Is still in the reset state, so SE4 to SE9
After setting BKR (SE9), the ON signal of the thermal head B is output (SE10). 5m continuously
s timer keeps thermal head B on for 5 ms
After continuing for a while (SE15), thermal head B is turned off.
A signal is issued (SE16) and the process returns to SE2.

Further, the user turns on the third transpiration ON SW.
When the operation of 25 is performed, since AKR and BKR are already set, the process proceeds from SE5 to SE11,
After setting CKR, the ON signal of the thermal head C is output (SE12). Also, the user turns on the fourth evaporation.
When SW25 is operated, AKR, BKR, C
Since KR has already been set, SE6 to SE1
Go to 3 and set the DKR, then the thermal head D
ON signal is output (SE14).

That is, in the fourth embodiment, the four registers A provided in the transpiration management memory KR are used.
Depending on the states of KR, BKR, CKR, and DKR, the already-evaporated area and the un-evaporated area in the chemical solution holding unit 17 are managed,
Each time the user operates the evaporation ON SW 25, the thermal heads A to D corresponding to the non-evaporated areas are sequentially heated. Therefore, the area that has already evaporated is not heated unnecessarily, and the evaporation ON SW2
By manipulating 5, it is possible to evaporate the drug from the non-evaporated region and surely obtain the desired drug effect.

25 to 31 show the fifth embodiment of the present invention. As shown in FIGS. 25 and 26, the evaporated chemical solution card 38 is provided on the rectangular base 16 and on the base 16. Similarly, it is composed of a rectangular drug solution holding portion 17. Further, the four-division thermal head 34 has four thermal heads A, B, C, and D, and these four thermal heads A to D have a rectangular shape corresponding to the shape of the chemical solution holding portion 17. Are arranged in.

Incidentally, in this fifth embodiment, FIG.
As shown in, the evaporation ON / OFF SW 39 and the piezoelectric buzzer 40 are provided. The circuit configurations of the thermal head driver 24 and the four-division thermal head 34 are the same as those of the third embodiment shown in FIG. However, the configuration of the RAM 37 is different from that of the fourth embodiment, and the evaporation number memory KR provided in the RAM 37 in the fifth embodiment has a transpiration count memory KR of 3 as shown in FIG.
It is a bit configuration, and depending on its value, 0; 1 time, 1 time, 2 times, 2 times, 3 times, 3 times, and 4 times respectively.

In the present embodiment having the above configuration, C
The PU 22 operates according to the main flow shown in FIG. 29, and first resets the evaporation number memory KR to 0 (SF
1). Next, wait until the evaporation ON / OFF SW39 is pressed (SF2), and if the evaporation ON / OFF SW39 is pressed, execute evaporation processing (SF3).

This transpiration process is performed according to the flowchart shown in FIG. 30, and it is determined whether KR is "0" (SG1). Then, if KR is in the state of "0" and the evaporation ON / OFF SW39 is operated for the first time this time, the ON signal of the thermal head A is output (SG1).
2). Subsequently, after the thermal head A is kept on for 3 ms by the 3 ms timer (SG15), the thermal head A OFF signal is output (SG16).

Therefore, the first evaporation ON / OFF
When the SW39 is operated, the thermal head A
Is heated for 3 ms, whereby the microcapsules in the region corresponding to the thermal head A in the chemical solution holding unit 17 are destroyed. As a result, the drug leaches from the microcapsules, and the leached drug spontaneously evaporates due to the ambient heat, whereby a predetermined drug effect is obtained.

Further, in the main flow of FIG. 29,
After completing the evaporation process (SF3), turn on evaporation again.
/ OFF Wait until SW39 is operated (SF4),
When the evaporation ON / OFF SW39 is operated for the second time, the evaporation end processing is executed (SF5). This transpiration ending process is executed according to the flowchart shown in FIG. 31, and it is determined whether KR is “0” (S).
H1). Then, if KR is in the state of "0", the ON signal of the thermal head A is output (SH10). Continuing,
KR is incremented (SH13) and then 10
The on state of the thermal head A is set to 10 by the ms timer.
After continuing for ms (SH14), O of thermal head A
The FF signal is output (SH15) and the process returns to SF2 of the main flow.

Therefore, this evaporation end processing (SF5)
When the chemical liquid holding unit 17 is executed, the portion heated by the evaporation process (SF2) for 3 ms is changed to 10 m again.
It will be heated for s. Therefore, the evaporation process (SF
The chemical that the microcapsules are broken and leached by 2) is heated for 10 ms in the transpiration termination process (SF5), whereby the transpiration is promoted.

That is, in this embodiment, the spontaneous evaporation by the destruction of the microcapsules and the positive evaporation by the heating are used together. Then, the user turns ON / OFF the first evaporation at any time when he or she wants to produce the drug effect.
When operating W39, 3m of thermal head A
The microcapsules are exclusively destroyed by heating. Along with the destruction of the microcapsules, the drug leaches out and spontaneously evaporates, so that a drug effect is generated in the surrounding space. Next, when the user operates the evaporation ON / OFF SW39 for the second time at the time when the drug effect due to the natural evaporation is reduced, the thermal head A is heated for 10 ms,
A region of the liquid medicine holding unit 17 in which the microcapsules are already destroyed is heated, whereby the drug evaporates from the region and a drug effect is generated in the surrounding space.

Further, in this way, the thermal head A
3ms heating and 10ms heating are performed and after returning to SF2 of the main flow, the user evaporates ON / OFF S
When W39 is pressed, the evaporation process (SF3) is executed again. At this time, since KR = 1 has already been entered, SG1 → SG2 → SG in the flowchart of FIG.
13, the ON signal of the thermal head B is output (SG
13). Subsequently, after the thermal head B is kept on for 3 ms by the 3 ms timer (SG15), an OFF signal of the thermal head B is output (SG16).

Therefore, the third evaporation ON / OFF
When SW39 is operated, the thermal head B
Is heated for 3 ms, whereby the microcapsules in the region corresponding to the thermal head B in the chemical solution holding unit 17 are destroyed. As a result, the drug leaches from the microcapsules, and the leached drug spontaneously evaporates due to the ambient heat, so that a predetermined drug effect is obtained.

Further, in the main flow of FIG. 29,
After completing the evaporation process (SF3), turn on evaporation again.
/ OFF Wait until SW39 is operated (SF4),
When the fourth evaporation ON / OFF SW39 is operated, the evaporation end processing is executed (SF5). At this time, since KR = 1 already, in the flowchart shown in FIG. 31, the process proceeds to SH1 → SH2 → SH11 to output the ON signal of the thermal head B. Subsequently, KR is incremented (SH13), after which the thermal head B is kept on for 10 ms by the 10 ms timer (SH14), then an OFF signal of the thermal head B is issued (SH15), and the flow returns to SF2 of the main flow.

After returning to SF2 in the main flow, when the user operates the evaporation ON / OFF SW39 for the fifth time, the evaporation process (SF3) is executed again. At this time, since KR = 2 is already in the state, SG1 → SG2 → SG3 → S in the flowchart of FIG.
Proceeding to G14, the ON signal of the thermal head C is output. Subsequently, after the thermal head C is kept on for 3 ms by the 3 ms timer (SG15), an OFF signal of the thermal head C is output (SG16).

Therefore, the fifth evaporation ON / OFF
When SW39 is operated, the thermal head C
Is heated for 3 ms, whereby the microcapsules in the region corresponding to the thermal head C in the chemical solution holding unit 17 are destroyed. As a result, the drug leaches from the microcapsules, and the leached drug spontaneously evaporates due to the ambient heat, so that a predetermined drug effect is obtained.

Further, in the main flow of FIG. 29,
After completing the evaporation process (SF3), turn on evaporation again.
/ OFF Wait until SW39 is operated (SF4),
When the sixth evaporation ON / OFF SW39 is operated, the evaporation end processing is executed (SF5). At this time, since KR = 2 has already been reached, in the flowchart shown in FIG. 31, the sequence proceeds to SH1 → SH2 → SH3 → SH12, and the ON signal of the thermal head C is output. Continuing,
KR is incremented (SH13) and then 10
The on state of the thermal head C is set to 10 by the ms timer.
After continuing for ms (SH14), O of thermal head C
The FF signal is output (SH15) and the process returns to SF2 of the main flow.

After returning to SF2 in the main flow, when the user operates the evaporation ON / OFF SW39 for the seventh time, the evaporation process (SF3) is executed again. At this time, since KR = 3 is already in the state, SG1 → SG2 → SG3 → S in the flowchart of FIG.
Proceeding to G4, the ON signal of the thermal head D is output. Subsequently, the piezoelectric buzzer 40 starts sounding (SG5), and 0.
After the sound of the piezoelectric buzzer 40 is continued for 0.5s by the 5s timer (SG6), the sound is stopped (SG7).

Furthermore, after the sounding of the piezoelectric buzzer 40 is stopped for 0.5s by the 0.5s timer (SG
8), the sound of the piezoelectric buzzer 40 is started again (SG9),
After this pronunciation is continued for 0.5 s (SG10), the pronunciation is stopped (SG11). Then, after the thermal head D is kept on for 3 ms by the 3 ms timer (SG15), an OFF signal of the thermal head D is output (SG16).

Therefore, the seventh evaporation ON / OFF
When the SW39 is operated, that is, the chemical solution holding unit 1
When the evaporation process and the evaporation end process of the portions corresponding to the thermal heads A, B, and C are completed in 7 and the evaporation process of the last region corresponding to the thermal head D is performed,
The buzzer sound is generated twice from the piezoelectric buzzer 40 at intervals of 0.5 seconds. As a result, the user can turn on / on this evaporation
It is recognized that by operating the FF SW 39, the microcapsules in the last region of the chemical solution holding unit 17 are destroyed and spontaneous evaporation occurs. Further, as a result of this recognition, it is possible to know that it is imminent when it is time to replace the new evaporated chemical liquid card 15.

Further, in the main flow of FIG. 29,
After completing the evaporation process (SF3), wait until the eighth operation of the evaporation ON / OFF SW39 (SF3).
4) If the 8th evaporation ON / OFF SW39 is operated, the evaporation end processing is executed (SF5). At this time, since KR = 3, SH1 → SH2 → SH3 → SH4 in the flowchart shown in FIG.
Then, the ON signal of the thermal head D is output. Then, after the thermal head D is kept on for 10 ms by the 10 ms timer (SH5), an OFF signal of the thermal head D is output (SH6). As a result, in the drug solution holding unit 17, the last region corresponding to the thermal head D in which the microcapsules have been destroyed by the evaporation process in advance is heated, the drug evaporates from the region, and the drug effect is generated in the surrounding space. To do.

Next, the sounding of the piezoelectric buzzer 40 is started (S
H7) 1s timer makes piezoelectric buzzer 40 sound 1
After continuing for s (SH8), the pronunciation is stopped (SH
9). Therefore, in the chemical solution holding unit 17, when the evaporation end processing of the last region is completed, the piezoelectric buzzer 40
From this, a buzzer sound is generated for one second, which allows the user to recognize that it is time to replace the new chemical liquid card 15.

32 to 39 show a sixth embodiment of the present invention. As shown in FIGS. 32 and 33, the evaporated chemical liquid card 38 includes a rectangular base 16 and one of the bases 16 on the base 16. It is composed of a rectangular drug solution holding part 17 provided on the side part. Also, the four-division thermal head 34
It has the same structure as that shown in FIG. 21, and has four thermal heads A, B, C, and D arranged along the longitudinal direction of the chemical liquid holding portion 17.

The sixth embodiment has the same structure as that of the fifth embodiment shown in FIG. 27, except that a transpiration inhibition canceling SW 41 is added as shown in FIG.
The circuit configurations of the thermal head driver 24 and the four-division thermal head 34 are similar to those of the third embodiment shown in FIG. However, the configuration of the RAM 37 is different from that of the fifth embodiment, and in this sixth embodiment, a 2-bit evaporation number memory KR (FIG. 35) and a 1-bit evaporation inhibition memory JR (FIG. 36) are provided. And the transpiration frequency memory K
Depending on its value, R indicates 0; 1 time 1; 2 times 2; 3 times 3; 4 times, and the evaporation prohibition memory JR indicates 0: evaporation possible 1; evaporation prohibited.

In the present embodiment having the above configuration, C
The PU 22 operates according to the main flow shown in FIG. 37, resets the evaporation number memory KR and the evaporation prohibition memory JR (SI1, SI2), and then turns ON / OFF the evaporation.
Wait until SW39 is pressed (SI3). Then, if the evaporation ON / OFF SW39 is pressed, it is judged whether or not the evaporation inhibition memory JR is in the reset state, that is, whether or not the evaporation is possible (SI4). Is executed (SI5).

This transpiration process is performed according to the flow chart shown in FIG. 38, and it is determined whether KR is "0" (SJ1). Then, if KR is in the state of "0" and the operation of the evaporation ON / OFF SW39 is the first time, the ON signal of the thermal head A is output (SJ
5). Subsequently, after the thermal head A is kept on for 3 ms by the 3 ms timer (SJ8), the thermal head A OFF signal is output (SJ9).

Therefore, the first evaporation ON / OFF
When the SW39 is operated, the thermal head A
Is heated for 3 ms, whereby the microcapsules in the region corresponding to the thermal head A in the chemical solution holding unit 17 are destroyed. As a result, the drug leaches from the microcapsules, and the leached drug spontaneously evaporates due to the ambient heat, whereby a predetermined drug effect is obtained.

Further, in the main flow of FIG. 37,
After completing the evaporation process (SI5), evaporation is turned on again
/ OFF Wait until SW39 is operated (SI6),
If the second evaporation ON / OFF SW39 is operated, the evaporation end processing is executed (SI7). This transpiration end process is executed according to the flowchart shown in FIG. 39, and it is determined whether KR is “0” (SK
1), if KR is "0", the thermal head A
Signal is output (SK8). Subsequently, KR is incremented (SK11), after which the ON state of the thermal head A is continued for 10 ms by the 10 ms timer (SK12), then an OFF signal of the thermal head A is issued (SK13), and the process returns to SI3 of the main flow.

Therefore, this evaporation end processing (SI7)
When the chemical liquid holding unit 17 is executed, the portion heated by the evaporation process (SI5) for 3 ms described above becomes 10 m again.
It will be heated for s. Therefore, the evaporation process (SI
The chemical that the microcapsules are destroyed and leached by 5) is heated for 10 ms in the evaporation end treatment (SI7), so that the evaporation is promoted.

That is, in this embodiment, as in the case of the fifth embodiment described above, the natural evaporation by the destruction of the microcapsules and the positive evaporation by the heating are used together. Then, when the user operates the evaporation ON / OFF SW 39 for the first time at an arbitrary time point where the drug effect is desired to be generated, the microcapsules are exclusively destroyed by heating the thermal head A for 3 ms. Along with the destruction of the microcapsules, the drug leaches out and spontaneously evaporates, so that a drug effect is generated in the surrounding space. Next, when the drug effect due to the natural evaporation is reduced, the user evaporates O for the second time.
When the N / OFF SW39 is operated, the thermal head A
By heating for 10 ms, the region where the microcapsules are already destroyed in the drug solution holding unit 17 is heated, whereby the drug evaporates from the region and the drug effect is generated in the surrounding space.

Further, in this way, the thermal head A
3ms heating and 10ms heating are performed and after returning to SI3 of the main flow, the user evaporates ON / OFF S
When W39 is pressed, the determination of SI4 is executed again. At this time, since JR = 0 still, the evaporation process in SI4 is executed. This transpiration processing is executed according to the flowchart of FIG. 38 in the same manner as described above, but KR = 1 at this point. Therefore, in the flowchart of FIG. 38, the process proceeds to SJ1 → SJ2 → SJ15,
The ON signal of the thermal head B is output. 3ms continuously
After the thermal head B is kept on for 3 ms by the timer (SJ8), the thermal head B OFF signal is output (SJ16).

Therefore, the third evaporation ON / OFF
When SW39 is operated, the thermal head B
Is heated for 3 ms, whereby the microcapsules in the region corresponding to the thermal head B in the chemical solution holding unit 17 are destroyed. As a result, the drug leaches from the microcapsules, and the leached drug spontaneously evaporates due to the ambient heat, so that a predetermined drug effect is obtained.

Further, in the main flow of FIG. 37,
After completing the evaporation process (SI5), evaporation is turned on again
/ OFF Wait until SW39 is operated (SI6),
When the fourth evaporation ON / OFF SW39 is operated, the evaporation end processing is executed (SI7). At this time, since KR = 1 already, the process proceeds to SK1 → SK2 → SK9 in the flowchart shown in FIG. 39 to output the ON signal of the thermal head B, and then increments KR (SK11). Then, after the thermal head B is kept on for 10 ms by the 10 ms timer (SK12), an OFF signal of the thermal head B is issued (SK13), and the process returns to SI3 of the main flow.

After returning to SI2 in the main flow, when the user operates the evaporation ON / OFF SW39 for the fifth time, SI4 is discriminated, but JR = 0 still at this point. , Transpiration treatment again (SI3)
Is executed. At this time, since KR = 2 is already in the state, SJ1 → S in the flowchart of FIG.
J2 → SJ3 → SJ7, and thermal head C is turned on.
Give a signal. After the thermal head C is kept on for 3 ms by the 3 ms timer (SJ1
5) Output an OFF signal for the thermal head C (SJ1
6).

Therefore, the fifth evaporation ON / OFF
When SW39 is operated, the thermal head C
Is heated for 3 ms, whereby the microcapsules in the region corresponding to the thermal head C in the chemical solution holding unit 17 are destroyed. As a result, the drug leaches from the microcapsules, and the leached drug spontaneously evaporates due to the ambient heat, so that a predetermined drug effect is obtained.

Further, in the main flow of FIG. 37,
After completing the evaporation process (SI5), evaporation is turned on again
/ OFF Wait until SW39 is operated (SI6),
When the sixth evaporation ON / OFF SW39 is operated, the evaporation end processing is executed (SI7). At this time, since KR = 3 has already been reached, in the flow chart shown in FIG. 39, the sequence proceeds to SK1 → SK2 → SK3 → SK10, and the ON signal of the thermal head C is output. Continuing,
KR is incremented (SK13), then 10
The on state of the thermal head C is set to 10 by the ms timer.
After continuing for ms (SK14), O of thermal head C
The FF signal is output (SK15), and the process returns to SI2 of the main flow.

Then, after returning to SI2 of the main flow, when the user operates the evaporation ON / OFF SW39 for the seventh time, SI4 is determined, but JR = 0 still at this point. , Transpiration treatment again (SI3)
Is executed. At this time, since KR = 3 is already in the state, SJ1 → S in the flowchart of FIG.
J2 → SJ3 → SJ4, thermal head D ON
Give a signal. Then, after the thermal head D is kept on for 3 ms by the 3 ms timer (SJ
8) Output the OFF signal of the thermal head D (SJ
9).

Further, in the main flow of FIG. 37,
After the execution of the evaporation process (SI5), wait until the eighth evaporation ON / OFF SW39 operation (SI
6) If the evaporation ON / OFF SW39 for the eighth time is operated, the evaporation end processing is executed (SI7). At this time, since KR = 3 already, in the flowchart shown in FIG. 39, SK1 → SK2 → SK3 → SK4
Then, the ON signal of the thermal head D is output. Then, after the thermal head D is kept on for 10 ms by the 10 ms timer (SK5), an OFF signal of the thermal head D is output (SK6). As a result, in the drug solution holding unit 17, the last region corresponding to the thermal head D in which the microcapsules have been destroyed by the evaporation process in advance is heated, the drug evaporates from the region, and the drug effect is generated in the surrounding space. To do.

When the last region is heated in this way, JR is set (SK1). Therefore,
When the ninth evaporation ON / OFF SW39 is operated, SI3 → SI4 in the main flow of FIG.
→ Proceed to SI8 to start sounding of the piezoelectric buzzer 40.
After that, the sound of the piezoelectric buzzer 40 is continued for 1s by the 1s timer (SK8), and then the sound is stopped (SK.
9). Further, it is determined whether or not the evaporation removal SW 41 has been pressed (SI11). If not, the process returns to SI3.

Therefore, without pressing the transpiration release SW41,
When the evaporation ON / OFF SW 39 is pressed 9 times or more, the buzzer sound is generated from the piezoelectric buzzer 40 for 1 second without heating any of the thermal heads A to D. This allows the user to turn on the evaporation ON / OF even though the entire area of the chemical solution holding unit 17 has finished evaporation.
Recognize that the FSW 39 is being pressed. Also, transpiration O
Even if the N / OFF SW 39 is operated, none of the thermal heads A to D performs a heating operation, so that the chemical solution holding portion 17 that already has no chemical solution to be evaporated does not needlessly heat.

Then, the user recognizes, by the buzzer sound from the piezoelectric buzzer 40, that all the areas of the chemical solution holding portion 17 have been evaporated, and after exchanging with a new evaporation chemical solution card 38, the evaporation inhibition is released. When SW41 is pressed, SI11 returns to SI1 in the main flow. Therefore, S
JR is reset at SI2 subsequent to I1, whereby the chemical liquid can be vaporized for each operation of the vaporization ON / OFF SW39 in the same manner as described above.

40 to 43 show a specific structure of the four-divided thermal head 34 used in the above-described sixth embodiment and the like. That is, as shown in FIG. 40, the four-division thermal head 34 is provided with the evaporated chemical liquid card 38.
It is arranged so as to be in close contact with the liquid medicine holding part 17. The four-division thermal head 34 has a substrate 42 shown in FIG.
And a resistor 43 laminated on the substrate 42 as shown in FIG. 42. The substrate 42 is formed of an insulating material such as ceramic, and has a comb-teeth-shaped common electrode 44, which has conductivity, on its surface.
Four heads 45A to 45D are provided between the comb teeth of the common electrode 44. The resistor 43 is fixed to the substrate 42 while being in contact with the upper surfaces of the common electrode 44 and the heads 45A to 45D.

Therefore, when the common electrode 44 is grounded and a current is supplied only to the head 45A, as shown in FIG. 43, a current flows between the common electrode 44 of the resistor 43 and the head 45A, Joule heat is generated at the site,
A heat generating area 46 is formed. Therefore, in the drug solution holding unit 17, only the portion in contact with the heat generating region 46 is heated, the microcapsules are destroyed, or the drug that has leached out due to the destruction of the microcapsules is evaporated. The same is true when a current is applied only to the other heads 45B, 45C, 45D, and the current flows between the common electrode 44 of the resistor 43 and the heads 45B, 45C, 45D, so that the heat generating area 46 is generated. It is formed. As a result, the chemical solution holding unit 17 can be heated in a time-sharing manner for each heat generation region.

As shown in FIGS. 44 and 45, when the vaporized chemical liquid card 50 in which the chemical liquid holding portion 17 having a small area is provided in the substantially central portion of the base 16, a thermal head 47 having a single head structure is used. To use. As shown in FIG. 46, the thermal head 47 of this single head structure has
Both are composed of a single common electrode 44 and a head 45, and a resistor 43 in contact with the common electrode 44 and the head 45. Therefore, if the common electrode 44 is grounded and a current is applied to the head 45, a heat generating region 46 is formed between the two.

Further, FIG. 47 shows a nine-division thermal head 4
8 structure, nine heads H1 to H9 are arranged in the vicinity of the peripheral portion of the common electrode 44, and a resistor (not shown) is provided in contact with the common electrode 44 and the heads H1 to H9. There is. Therefore, if the common electrode 44 is grounded and a current is applied to the heads H1 to H9 in a time division manner, the heating regions P1 to P9 are sequentially formed.

Further, FIG. 48 shows the structure of the 14-division thermal head 49, in which 1 is provided near the peripheral portion of the common electrode 44.
Four heads H1 to H14 are arranged, and the common electrode 4
A resistor (not shown) is provided in a state where 4 is in contact with each of the heads H1 to H14. Therefore, if the common electrode 44 is similarly grounded and a current is applied to the heads H1 to H14 in a time division manner, the heating regions P1 to P14 are sequentially formed.

[0079]

As described above, according to the present invention, the drug portion holding the drug and the heating means having a plurality of heating surfaces for heating corresponding parts of the drug portion are provided, and The heating state of the heating surface of was controlled. Therefore, it is possible to heat the medicine part in each region corresponding to the heating surface and evaporate a large amount of medicine each time it is heated. Therefore,
As in the past, the amount of transpiration does not gradually decrease with the lapse of the usage period, and the amount of transpiration is made variable to stimulate the olfactory sense, and the effect of making the bactericidal effect variable, etc. It is possible to evaporate a specific drug.

Further, if any one of the heating surfaces is heated, it becomes possible to evaporate the drug, so that the current required for evaporation per unit time can be reduced. As a result, even if a battery is used, sufficient evaporation can be achieved over a long period of time, which makes it possible to realize a portable evaporation device.

Further, by sequentially heating the plurality of heating surfaces in a time-division manner, the medicine can be efficiently evaporated from the medicine part, and by variably controlling the number of heating surfaces to be heated, It is possible to evaporate the medicine in an amount suitable for the volume of the space in which the medicine is to be evaporated. Further, since the medicine is applied to each area corresponding to the heating surface in the medicine part, the applied medicine can be evaporated without remaining, and a different medicine is applied to each area. Therefore, one evaporation device can be used for multiple purposes.

Further, by forming a drug portion by applying a microcapsule formed by sealing a drug onto the base, the drug can be evaporated only during use, and unnecessary drug evaporation can be prevented. Further, by performing the primary heating for a time length in which the microcapsules are dissolved and then performing the secondary heating for a time length capable of enhancing the evaporation efficiency of the drug, a more variable drug evaporation can be achieved.

Further, by memorizing which heating surface is secondarily heated, it is possible to prevent duplicate heating, and to detect that all the heating surfaces are secondarily heated and issue a warning. Alternatively, a warning can be issued when a predetermined number of heating surfaces that have not been subjected to secondary heating remain, thereby making it possible for the user to recognize the end of evaporation. Furthermore, when all the heating surfaces have finished the secondary heating, it is possible to avoid power consumption due to unnecessary heating by prohibiting the heating operation of the heating surfaces, and all the heating surfaces have finished the secondary heating. Later, by invalidating a heating instruction from the outside, unnecessary heating can be prevented and safety can be improved. Further, by providing the releasing means for releasing the invalid state, it becomes possible to easily continue the use.

In addition, it is possible to achieve a heating means capable of time-division control and the like with a simple structure including a flat substrate, a conductive layer laminated on the flat substrate and having a plurality of electrodes, and a resistor. Since the heating surface is in close contact with the drug part, the drug part can be heated without wasting energy.

[Brief description of drawings]

FIG. 1 is a cross-sectional view of an evaporation device common to each embodiment of the present invention.

FIG. 2 (A) is a plan view of a vaporized drug solution card used in the first embodiment of the present invention, and FIG. 2 (B) is a sectional view taken along line aa in FIG. 2 (A).

FIG. 3 is a schematic diagram of a thermal head of the same embodiment.

FIG. 4 is a block diagram showing the overall configuration of the same embodiment.

FIG. 5 is a block circuit diagram showing a connection structure of the thermal head and the thermal head driver of the embodiment.

FIG. 6 is a main flow of the embodiment.

FIG. 7 is a flowchart showing the control contents of each dot of the same embodiment.

FIG. 8 is a plan view of a vaporized drug solution card used in a second embodiment of the present invention.

FIG. 9 is a schematic view of a thermal head of the same example.

FIG. 10 is a block diagram showing an overall configuration of the embodiment.

FIG. 11 is a block circuit diagram showing a connection structure of the thermal head and the thermal head driver of the embodiment.

FIG. 12 is a flowchart of the same embodiment.

FIG. 13 is a plan view of a vaporized drug solution card used in a third embodiment of the present invention.

14 is a cross-sectional view taken along the line bb of FIG.

FIG. 15 is a schematic view of the thermal head of the same example.

FIG. 16 is a block diagram showing an overall configuration of the same example.

FIG. 17 is a block circuit diagram showing a connection structure between the thermal head and the thermal head driver of the embodiment.

FIG. 18 is a flowchart of the same embodiment.

FIG. 19 is a plan view of a vaporized drug solution card used in a fourth embodiment of the present invention.

20 is a cross-sectional view taken along the line cc of FIG.

FIG. 21 is a schematic view of the thermal head of the same example.

FIG. 22 is a block diagram showing the overall configuration of the same example.

FIG. 23 is a conceptual diagram showing a transpiration management memory of the same embodiment.

FIG. 24 is a flowchart of the same embodiment.

FIG. 25 is a plan view of a vaporized drug solution card used in a fifth embodiment of the present invention.

26 is a cross-sectional view corresponding to line dd of FIG. 25.

FIG. 27 is a block diagram showing an overall configuration of the same example.

FIG. 28 is a conceptual diagram showing a transpiration frequency memory of the same embodiment.

FIG. 29 is a main flow of the same example.

FIG. 30 is a flowchart showing the contents of the evaporation process of the same example.

FIG. 31 is a flowchart showing the contents of transpiration end processing in the same example.

FIG. 32 is a plan view of a vaporized drug solution card used in a sixth embodiment of the present invention.

FIG. 33 is a cross-sectional view taken along the line ee of FIG. 32.

FIG. 34 is a block diagram showing an overall configuration of the same example.

FIG. 35 is a conceptual diagram showing a transpiration frequency memory of the same embodiment.

FIG. 36 is a conceptual diagram showing a transpiration prohibition memory of the same embodiment.

FIG. 37 is a main flow of the same embodiment.

FIG. 38 is a flowchart showing the contents of the evaporation process of the same example.

FIG. 39 is a flowchart showing the contents of transpiration end processing in the same example.

FIG. 40 is a cross-sectional view corresponding to the line ee of FIG. 32.

FIG. 41 is a plan view showing the configuration of the first layer of the four-division thermal head.

FIG. 42 is a plan view of a 4-division thermal head.

FIG. 43 is a main-portion plan view showing a heating state of the thermal head.

FIG. 44 is a plan view of a vaporized drug solution card heated by a thermal head having a single head structure.

45 is a cross-sectional view corresponding to line ff of FIG. 44.

FIG. 46 is a plan view showing a heat generation area of a thermal head having a single head structure.

FIG. 47 is a schematic view showing the structure of a nine-division thermal head.

FIG. 48 is a schematic view showing the structure of a 14-division thermal head.

FIG. 49 is a vertical sectional view of an apparatus main body and a chemical liquid cartridge showing a conventional evaporation device.

FIG. 50 is a vertical cross-sectional view of the apparatus main body of the apparatus with a chemical liquid cartridge loaded.

[Explanation of symbols]

1 Evaporator 9 batteries 12 Transpiration port 15 Evaporative drug card 17 Chemical solution holder 21 Control LSI 22 CPU 23 ROM 24 Thermal head driver 25 Transpiration ON SW 26 Heating resistor 28 3 division thermal head 34 4-division thermal head

Continuation of the front page (56) Reference JP-A-3-97464 (JP, A) JP-A 1-210488 (JP, A) JP-A 63-171563 (JP, A) JP-A 59-62057 (JP , A) JP 56-23834 (JP, A) JP 51-129772 (JP, A) JP 2-116378 (JP, A) JP 2-5958 (JP, A) JP 1-297067 (JP, A) Jitsuhei 3-45174 (JP, Y2) (58) Fields investigated (Int.Cl. ⁷ , DB name) A61L 9/03 A01N 25/00 A01N 25/18

Claims (2)

(57) [Claims] 1. A medicine part holding a transpigable medicine, a heating means having a plurality of heating surfaces for heating corresponding parts of the medicine part, and a heating state of the plurality of heating surfaces. have a control means for controlling said heating means, of laminating a planar substrate, on the planar substrate
And a conductive layer having a plurality of electrodes and stacked on this conductive layer.
Transpiration apparatus characterized by comprising a resistor body. 2. A medicine part holding a transpigable medicine, a heating means having a plurality of heating surfaces for respectively heating corresponding parts of the medicine part, and a heating state of the plurality of heating surfaces. have a control means for controlling said heating means includes a single common electrode, a plurality of individual electrodes
And the control means is separate from the common electrode.
An energized state is formed with the electrode to heat the corresponding heating surface.
A transpiration device characterized by being made to work .